$ATHX We know Nikon Cell, what about Sumitomo Dainippon Pharma? Hardy formed a JV w/ them in 2014, to form Sighregen Ltd. using IPS epithelial cells to treat AMD( sound familiar). SDP’s stated goal is ‘post-Latuda replacement revenue’ ($BILS) and to be a global leader in RMAT. To which they built a facility “ dedicated to the commercial manufacture of Regenerative Medicines & Cell Therapies using allogeneic IPS cells. “ So where are they getting these stem cells?? I only know of Athx and Psti with allogeneic IPS patents... I assume there must be others.